NS-11394
Identifiers | |
---|---|
| |
CAS Number | 951650-22-9 |
PubChem (CID) | 16747643 |
ChemSpider | 20578861 |
Chemical and physical data | |
Formula | C23H19N3O |
Molar mass | 353.416 g/mol |
3D model (Jmol) | Interactive image |
| |
| |
(what is this?) (verify) |
NS-11394 is a drug which acts as a subtype-selective positive allosteric modulator at GABAA receptors, with selectivity for the α3 and α5 subtypes.[1][2] It has been researched as an analgesic for use in chronic or neuropathic pain.[3]
References
- ↑ Munro G, Lopez-Garcia JA, Rivera-Arconada I, Erichsen HK, Nielsen E, Larsen JS, Ahring PK, Mirza NR (December 2008). "Comparison of the novel subtype-selective GABAA receptor-positive allosteric modulator NS11394 [3'-[5-(1-hydroxy-1-methyl-ethyl)-benzoimidazol-1-yl]-biphenyl-2-carbonitrile] with diazepam, zolpidem, bretazenil, and gaboxadol in rat models of inflammatory and neuropathic pain". The Journal of Pharmacology and Experimental Therapeutics. 327 (3): 969–81. doi:10.1124/jpet.108.144568. PMID 18791060.
- ↑ Mirza NR, Larsen JS, Mathiasen C, Jacobsen TA, Munro G, Erichsen HK, Nielsen AN, Troelsen KB, Nielsen E, Ahring PK (December 2008). "NS11394 [3'-[5-(1-hydroxy-1-methyl-ethyl)-benzoimidazol-1-yl]-biphenyl-2-carbonitrile], a unique subtype-selective GABAA receptor positive allosteric modulator: in vitro actions, pharmacokinetic properties and in vivo anxiolytic efficacy". The Journal of Pharmacology and Experimental Therapeutics. 327 (3): 954–68. doi:10.1124/jpet.108.138859. PMID 18791063.
- ↑ Munro G, Ahring PK, Mirza NR (September 2009). "Developing analgesics by enhancing spinal inhibition after injury: GABAA receptor subtypes as novel targets". Trends in Pharmacological Sciences. 30 (9): 453–9. doi:10.1016/j.tips.2009.06.004. PMID 19729210.
This article is issued from Wikipedia - version of the 6/4/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.